ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study.

ABSTRACT:

Introduction

In this study (PRECISE), we assess the clinical utility of a germline DNA sequencing-based test (ToxNav) for mutations in DPYD and ENOSF1 genes to alter clinician-prescribed fluoropyrimidine doses and the use of a digital application (PROMinet) to record patient-reported chemotherapy toxicity.

Materials and methods

Adult patients with a histological diagnosis of colorectal cancer (CRC) who consented to fluoropyrimidine-based chemotherapy were recruited prospectively and given a digital application to monitor and record associated toxicities. Patient samples were analyzed for 18 germline coding variants in DPYD and 1 ENOSF1 variant.

Results

Genetic testing was performed for 60 patients and identified one patient at increased risk of fluoropyrimidine-based

SUBMITTER: Lee LYW 

PROVIDER: S-EPMC6797583 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature